Full text is available at the source.
Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy
Using lipid nanoparticles to deliver mRNA for gene editing and CAR T cell treatments in heart diseases
AI simplified
Abstract
Cardiovascular diseases (CVDs) account for the leading cause of global mortality among non-communicable diseases.
- Current cardiac regeneration treatments have limitations and may lead to adverse reactions.
- Messenger RNA (mRNA) shows potential as a therapeutic agent due to its ability to encode proteins and target difficult conditions.
- mRNA offers low toxicity and high efficiency in delivering proteins without altering the genome.
- Challenges for mRNA include immunogenicity, instability, and issues with entering cells, which can impede its clinical use.
- Lipid nanoparticles (LNPs) are emerging as effective delivery systems for mRNA, particularly in the context of CVDs.
- Advanced technologies, including artificial intelligence, may improve the design and formulation of mRNA-LNP therapies.
AI simplified